In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of McDermott International,
Inc. (NYSE:MDR), Nu Skin Enterprises, Inc. (NYSE:NUS), Marcus
Corporation (NYSE:MCS), Keysight Technologies Inc. (NYSE:KEYS),
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), and LendingTree, Inc.
(NASDAQ:TREE), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified
analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
MDR DOWNLOAD: http://Capital-Review.com/register/?so=MDR
NUS DOWNLOAD: http://Capital-Review.com/register/?so=NUS MCS
DOWNLOAD: http://Capital-Review.com/register/?so=MCS KEYS DOWNLOAD:
http://Capital-Review.com/register/?so=KEYS ALDR DOWNLOAD:
http://Capital-Review.com/register/?so=ALDR TREE DOWNLOAD:
http://Capital-Review.com/register/?so=TREE
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine McDermott
International, Inc. (NYSE:MDR), Nu Skin Enterprises, Inc.
(NYSE:NUS), Marcus Corporation (NYSE:MCS), Keysight Technologies
Inc. (NYSE:KEYS), Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), and
LendingTree, Inc. (NASDAQ:TREE) on a fundamental level and outlines
the overall demand for their products and services in addition to
an in-depth review of the business strategy, management discussion,
and overall direction going forward. Several excerpts from the
recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in
this release was accessed February 27th, 2019. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
MCDERMOTT INTERNATIONAL, INC. (MDR) REPORT
OVERVIEW
McDermott International's Recent Financial
Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, McDermott International reported revenue
of $2,289.00MM vs $959.00MM (up 138.69%) and analysts estimated
basic earnings per share $0.01 vs $1.00 (down 99.00%). For the
twelve months ended December 31st, 2017 vs December 31st, 2016,
McDermott International reported revenue of $2,984.77MM vs
$2,635.98MM (up 13.23%) and analysts estimated basic earnings per
share $1.95 vs $0.42 (up 364.33%). Analysts expect earnings to be
released on April 23rd, 2019. The report will be for the fiscal
period ending March 31st, 2019. The reported EPS for the same
quarter last year was $0.51. The estimated EPS forecast for the
next fiscal year is $2.48 and is expected to report on February
24th, 2020.
To read the full McDermott International, Inc. (MDR) report,
download it here:
http://Capital-Review.com/register/?so=MDR
-----------------------------------------
NU SKIN ENTERPRISES, INC. (NUS) REPORT
OVERVIEW
Nu Skin Enterprises' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Nu Skin Enterprises reported revenue of
$683.29MM vs $666.20MM (up 2.56%) and analysts estimated basic
earnings per share -$0.33 vs $0.35. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Nu Skin Enterprises
reported revenue of $2,679.01MM vs $2,279.10MM (up 17.55%) and
analysts estimated basic earnings per share $2.21 vs $2.45 (down
9.80%). Analysts expect earnings to be released on April 25th,
2019. The report will be for the fiscal period ending March 31st,
2019. Reported EPS for the same quarter last year was $0.64. The
estimated EPS forecast for the next fiscal year is $4.27 and is
expected to report on February 12th, 2020.
To read the full Nu Skin Enterprises, Inc. (NUS) report,
download it here:
http://Capital-Review.com/register/?so=NUS
-----------------------------------------
MARCUS CORPORATION (MCS) REPORT OVERVIEW
Marcus' Recent Financial Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, Marcus reported revenue of $170.60MM vs
$162.38MM (up 5.06%) and analysts estimated basic earnings per
share $0.58 vs $0.39 (up 48.72%). For the twelve months ended
December 31st, 2017 vs December 31st, 2016, Marcus reported revenue
of $622.71MM vs $543.86MM (up 14.50%) and analysts estimated basic
earnings per share $2.34 vs $1.38 (up 69.57%). Analysts expect
earnings to be released on April 25th, 2019. The report will be for
the fiscal period ending March 31st, 2019. Reported EPS for the
same quarter last year was $0.35. The estimated EPS forecast for
the next fiscal year is $2.16 and is expected to report on February
20th, 2020.
To read the full Marcus Corporation (MCS) report, download it
here:
http://Capital-Review.com/register/?so=MCS
-----------------------------------------
KEYSIGHT TECHNOLOGIES INC. (KEYS) REPORT
OVERVIEW
Keysight Technologies' Recent Financial
Performance
For the three months ended October 31st, 2018 vs
October 31st, 2017, Keysight Technologies reported revenue of
$1,047.00MM vs $878.00MM (up 19.25%) and basic earnings per share
-$0.60 vs -$0.25. For the twelve months ended October 31st, 2018 vs
October 31st, 2017, Keysight Technologies reported revenue of
$3,878.00MM vs $3,189.00MM (up 21.61%) and analysts estimated basic
earnings per share $0.88 vs $0.57 (up 54.39%). Analysts expect
earnings to be released on May 29th, 2019. The report will be for
the fiscal period ending April 30th, 2019. The reported EPS for the
same quarter last year was $0.77. The estimated EPS forecast for
the next fiscal year is $3.99 and is expected to report on November
19th, 2019.
To read the full Keysight Technologies Inc. (KEYS) report,
download it here:
http://Capital-Review.com/register/?so=KEYS
-----------------------------------------
ALDER BIOPHARMACEUTICALS, INC. (ALDR) REPORT
OVERVIEW
Alder BioPharmaceuticals' Recent Financial
Performance
For the twelve months ended December 31st, 2017
vs December 31st, 2016, Alder BioPharmaceuticals reported revenue
of $1.62MM vs $0.11MM (up 1,332.74%) and analysts estimated basic
earnings per share -$4.95 vs -$3.23. Analysts expect earnings to be
released on May 14th, 2019. The report will be for the fiscal
period ending March 31st, 2019. The reported EPS for the same
quarter last year was -$1.73. The estimated EPS forecast for the
next fiscal year is -$2.87 and is expected to report on February
24th, 2020.
To read the full Alder BioPharmaceuticals, Inc. (ALDR) report,
download it here:
http://Capital-Review.com/register/?so=ALDR
-----------------------------------------
LENDINGTREE, INC. (TREE) REPORT OVERVIEW
LendingTree's Recent Financial Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, LendingTree reported revenue of $197.06MM
vs $171.49MM (up 14.91%) and analysts estimated basic earnings per
share $2.01 vs $0.76 (up 164.47%). For the twelve months ended
December 31st, 2017 vs December 31st, 2016, LendingTree reported
revenue of $617.74MM vs $384.40MM (up 60.70%) and analysts
estimated basic earnings per share $1.30 vs $2.33 (down 44.21%).
Analysts expect earnings to be released on April 25th, 2019. The
report will be for the fiscal period ending March 31st, 2019. The
reported EPS for the same quarter last year was $0.51. The
estimated EPS forecast for the next fiscal year is $7.53 and is
expected to report on February 25th, 2020.
To read the full LendingTree, Inc. (TREE) report, download it
here:
http://Capital-Review.com/register/?so=TREE
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Nicole Garrens, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
McDermott (NYSE:MDR)
Historical Stock Chart
From Jun 2024 to Jul 2024
McDermott (NYSE:MDR)
Historical Stock Chart
From Jul 2023 to Jul 2024